Project Grant R21AI183125
Award Date
6/20/25
Completion Date
5/31/26
Dollars Obligated
$426K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $456,000 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Texas Medical Branch at Galveston (UTMB) to investigate how regulatory mechanisms shape the interleukin-6 (IL-6) immune response during respiratory viral infections. The two-year grant (July 2024 - June 2026) aims to understand how changes in a cis-regulatory element control IL-6 expression in mucosal epithelial cells,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $218,068 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to St. Jude Children's Research Hospital Inc. The grant, titled "IMPACT OF OBESITY ON ANTIVIRAL NK CELL FUNCTION AND IMMUNE CROSSTALK WITH RESPIRATORY EPITHELIAL CELLS DURING INFLUENZA VIRUS INFECTION", will fund research to investigate the impact of obesity on natural killer (NK) cell antiviral responses and the...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $667,013 Project Grant to The University of Texas Southwestern Medical Center, doing business as Southwestern Medical School, for a 5-year period from March 1, 2025 to February 28, 2030. The grant supports the development and validation of deep learning models to accurately identify antibody-antigen interactions and binding epitopes on antigens...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant valued at $718,758 to the Texas Biomedical Research Institute under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is focused on evaluating the use of IL-21-IgFc fusion protein as a host-directed immunotherapy to improve immune reconstitution and reduce the risk of latent tuberculosis (TB) reactivation in Mycobacterium tuberculosis (MTB) and simian immunodeficiency virus (SIV)...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $185,280 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Texas A&M University System Health Science Center to study how the Mycobacterium tuberculosis (MTB) secreted protein Rv1075c hijacks host histone methyltransferases to promote infection. The key objectives are to define how histone methylation changes at innate immune genes during MTB infection, and investigate how...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $92,809,964 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Texas Medical Branch at Galveston (UTMB) on July 30, 2024. The PARAMYXOVIRIDAE AND BUNYAVIRALES VACCINES AND ANTIBODIES CENTER (PABVAX) project will focus on developing, testing, and translating prototype subunit vaccines using a novel microneedle patch platform, as well as developing new...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $704,041 to the Regents of the University of California at Riverside to investigate sex-dependent innate immune mechanisms in type 2 immunity and obesity. The research aims to: 1) Study sex differences in macrophage and eosinophil function and their role in protecting against diet-induced obesity and helminth...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 2-year Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) worth $162,000 to The Johns Hopkins University to study how atypical B cells can be used to enhance vaccine responses in immunosuppressed individuals. The research project aims to define populations of immunosuppressed individuals who utilize these atypical CD11c+ B cells, assess their interaction with T cells, and target fatty acid oxidation...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $711,993 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Boston Medical Center Corporation (BMC) on June 11, 2025. The grant supports research to understand the effects of Mycobacterium tuberculosis (MTB) disease on HIV-1 pathogenesis, immunity, and persistence in people living with HIV. Specifically, the project will assess how MTB disease impacts the HIV-1 immune response,...
This federal Project Grant award of $586,250 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research program supports research to investigate how distinct age-associated B cell subsets can protect the aged from influenza. The project aims to determine the potential of different age-associated B cell subsets to respond to influenza infection and generate antibody-secreting cells, B cell memory, and long-lived...